Two large randomized Phase II studies (IDEAL 1 and IDEAL 2) in pretreated non-small cell lung cancer reported a response rate approaching 20% in second-line patients and ∼10% in those pretreated with two or more chemotherapy regimens.
Izifundo ezimbili ezinkulu ezingahleliwe zeSigaba II (IDEAL 1 ne-IDEAL 2) kumdlavuza wamaphaphu wamangqamuzana ongeyona amancane owenziwe ngaphambi kwesikhathi wabika izinga lokuphendula elisondela kuma-20% ezigulini zomugqa wesibili kanye no-%10% kulabo ababelethwe ngemithi emibili noma ngaphezulu yamakhemikhali.